Skip to main content
. Author manuscript; available in PMC: 2015 Jan 1.
Published in final edited form as: Stem Cells. 2014 Jan;32(1):16–25. doi: 10.1002/stem.1506

Figure 3. Schematic illustrating the range of in vitro immune-modulating effects described for mesenchymal stromal (stem) cells (MSCs).

Figure 3

Ang 1 angiopoietin 1;EGF epidermal growth factor; eNOS endothelial nitric oxide synthase; FGF2 fibroblast growth factor 2; HGF = hepatocyte growth factor; IGF1 insulin-like growth factor; (s)IL -1RA = (soluble) interleukin-1 receptor antagonist; IL-10 interleukin 10; KGF keratinocyte growth factor; soluble TNFR1 = soluble tumor necrosis factor-α receptor antagonist; stanniocalcin 1; TGF-β1 = transforming growth factor- β1; TSG-6 Tumor necrosis factor-inducible gene 6 protein; VEGF = vascular endothelial growth factor. Adapted with permission from Weiss DJ and Rojas M. MSCs in Chronic Lung Diseases: COPD and Lung Fibrosis. In Stem Cell-Dependent Therapies (2013), Copyright DeGruyter Publisher GmbH Berlin, G. Gross G, T. Häupl, editors (117).